Unlikely to cause harm — often a labeling or packaging issue.
Failed Impurities/Degradation Specifications
| Brand name | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE |
| Generic name | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE |
| Distributed by / for | Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430 |
| NDC | 68462-879-01 |
| Full product label | Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, RX only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC 68462-879-01 |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | Nationwide in the USA |
| Quantity | 480 100-count bottles |
| Recall initiated | 2023-10-20 |
| Report date | 2023-11-08 |
| Recall completed | 2024-08-16 |
| Recall number | D-0085-2024 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Mahwah NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗